Roche Diabetes Care v. Trividia Health: Blood Glucose Strip Patents Dismissed With Prejudice
Roche Diabetes Care filed suit in Delaware against Trividia Health, asserting two patents covering blood glucose test strip technology used in the TRUE METRIX® product line. After 500 days of litigation, the parties reached a stipulated dismissal with prejudice — foreclosing any future re-filing of the same claims.
Roche vs. Trividia: A Diagnostic Patent Dispute Resolved by Stipulation
On June 4, 2024, Roche Diabetes Care, Inc. filed an infringement action in the U.S. District Court for the District of Delaware against Trividia Health, Inc., asserting two patents — US7727467B2 and US7892849B2 — directed to blood glucose test strip technology. The accused products were Trividia’s TRUE METRIX® PRO Test Strips and TRUE METRIX® Test Strips, commercially significant products in the point-of-care blood glucose monitoring market. The case was assigned to Judge Gregory B. Williams.
On October 17, 2025 — approximately 500 days after filing — the parties filed a joint stipulation under Federal Rule of Civil Procedure 41(a)(1)(A)(ii) dismissing all claims and counterclaims with prejudice. Each party agreed to bear its own attorneys’ fees and costs. A dismissal with prejudice is a final adjudication on the merits, meaning Roche cannot re-file the same patent claims against Trividia in any future action. The mutual cost-bearing arrangement suggests a negotiated resolution rather than a clear-cut capitulation by either side.
A 500-day timeline to a stipulated dismissal with prejudice is consistent with a negotiated commercial resolution — potentially a licensing agreement, cross-licensing arrangement, or product design-around — reached after meaningful discovery or claim construction work. The public record does not disclose the commercial terms, if any, that accompanied the stipulation. What remains unknown is whether Trividia obtained a license to the asserted patents or whether Roche concluded that continued enforcement was no longer commercially justified.
Filing to Dismissed with Prejudice in 500 days
500 days from filing to stipulated dismissal — consistent with pre-trial resolution
Dismissed with prejudice: what the stipulation means for both parties
Rule 41 stipulated dismissal with prejudice explained
Under Federal Rule of Civil Procedure 41(a)(1)(A)(ii), parties may jointly stipulate to dismiss an action. When the dismissal is ‘with prejudice,’ it functions as a final judgment on the merits. Roche is permanently barred from asserting the same patent claims — US7727467B2 and US7892849B2 — against Trividia in a future action. This is the strongest form of consensual dismissal available to litigants.
Rule 41(a)(1)(A)(ii) — final on meritsRoche forfeits the right to re-litigate these claims against Trividia
By agreeing to dismissal with prejudice, Roche permanently relinquishes its infringement claims under US7727467B2 and US7892849B2 against Trividia’s TRUE METRIX® product line. This does not invalidate the patents themselves — Roche retains them and may enforce them against other parties. The commercial rationale for accepting this outcome is not disclosed in the public record, but typically suggests a negotiated arrangement or strategic reassessment.
Patents survive; claims against Trividia closedTrividia secures permanent closure of Roche’s patent claims
Trividia achieves a legally durable outcome: Roche cannot reassert the same infringement claims for the TRUE METRIX® PRO and TRUE METRIX® Test Strips. The mutual cost-bearing provision means Trividia incurred its own defense costs without any fee-shifting award. Whether Trividia obtained a formal license, modified its products, or simply resolved the dispute commercially is not reflected in the public docket.
No fee award; claims permanently barredSector signal: blood glucose IP disputes increasingly resolve pre-trial
This resolution is consistent with a broader pattern in the point-of-care diagnostics sector, where incumbent patent holders and device manufacturers often resolve disputes through licensing or commercial arrangements rather than full trial. Competitors in the blood glucose monitoring space should note that US7727467B2 and US7892849B2 remain active and enforceable against third parties despite this dismissal. Freedom-to-operate assessments for test strip products should account for Roche’s continued patent portfolio activity.
Patents remain live vs. third partiesFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Roche Diabetes Care, Inc. | Company | Diagnostics division of Roche Group — holder of US7727467B2 and US7892849B2Search in Eureka ↗ |
| Defendant | Trividia Health, Inc. | Company | Blood glucose monitoring device and test strip manufacturer; maker of TRUE METRIX® productsSearch in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Roche Diabetes Care, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Benjamin T. Morris | Attorney | Counsel for Roche Diabetes Care, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Roche Diabetes Care, Inc.Search in Eureka ↗ |
| Plaintiff counsel | David P. Yin | Attorney | Counsel for Roche Diabetes Care, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Kelly A. Todd | Attorney | Counsel for Roche Diabetes Care, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Kim U. Do | Attorney | Counsel for Roche Diabetes Care, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Maliheh Zare | Attorney | Counsel for Roche Diabetes Care, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Omar A. Khan | Attorney | Counsel for Roche Diabetes Care, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Robert J. Gunther , Jr. | Attorney | Counsel for Roche Diabetes Care, Inc.Search in Eureka ↗ |
| Plaintiff counsel | S. Dennis Wang | Attorney | Counsel for Roche Diabetes Care, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Sarah J. Murphy | Attorney | Counsel for Roche Diabetes Care, Inc.Search in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Roche Diabetes Care, Inc.Search in Eureka ↗ |
| Defendant counsel | Benjamin J. Schladweiler | Attorney | Counsel for Trividia Health, Inc.Search in Eureka ↗ |
| Defendant counsel | Callie Sand | Attorney | Counsel for Trividia Health, Inc.Search in Eureka ↗ |
| Defendant counsel | Elana B. Araj | Attorney | Counsel for Trividia Health, Inc.Search in Eureka ↗ |
| Defendant counsel | Ewa Wojciechowska | Attorney | Counsel for Trividia Health, Inc.Search in Eureka ↗ |
| Defendant counsel | Herbert H. Finn | Attorney | Counsel for Trividia Health, Inc.Search in Eureka ↗ |
| Defendant counsel | Maja E. Sherman | Attorney | Counsel for Trividia Health, Inc.Search in Eureka ↗ |
| Defendant counsel | Patrick J. Owens | Attorney | Counsel for Trividia Health, Inc.Search in Eureka ↗ |
| Defendant counsel | Renee Mosley Delcollo | Attorney | Counsel for Trividia Health, Inc.Search in Eureka ↗ |
| Defendant counsel | Rose C. Prey | Attorney | Counsel for Trividia Health, Inc.Search in Eureka ↗ |
| Defendant counsel | Steven Laxton | Attorney | Counsel for Trividia Health, Inc.Search in Eureka ↗ |
| Defendant law firm | Greenberg Traurig PA | Law Firm | Representing Trividia Health, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Gregory B. Williams | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation explicitly invokes Rule 41(a)(1)(A)(ii) and specifies dismissal ‘WITH PREJUDICE’ — language that carries significant legal weight. It constitutes a final adjudication, permanently extinguishing Roche’s right to reassert US7727467B2 and US7892849B2 against Trividia’s TRUE METRIX® products. The symmetrical cost allocation — each party bearing its own fees — is notable: it signals a negotiated commercial resolution rather than a litigation victory for either side, and is consistent with an undisclosed licensing or settlement arrangement.
US7727467B2 & US7892849B2 — Blood Glucose Test Strip Technology
US7727467B2 (application no. US10/871673) and US7892849B2 (application no. US12/389954) are Roche Diabetes Care patents directed to blood glucose test strip technology — a core component of point-of-care glucose monitoring systems. These patents cover electrochemical biosensor structures, strip compositions, and related manufacturing methods that underpin the accuracy and reliability of blood glucose measurement. The application lineage suggests the portfolio spans both early platform development and subsequent refinements.
For a diagnostics company of Roche’s scale, these patents represent strategic IP in a high-volume consumable market where test strip design is a key differentiator. The TRUE METRIX® product line is positioned in the value segment of the glucose monitoring market, making the asserted claims commercially material. Competitors developing or commercialising electrochemical glucose test strips should treat both patents as active enforcement assets — particularly given that the dismissal here does not affect their validity or Roche’s right to assert them against other parties.
Should you run an FTO against US7727467B2 and US7892849B2?
Any company designing, manufacturing, or commercialising blood glucose test strips — particularly electrochemical biosensor-based strips — should assess freedom-to-operate against US7727467B2 and US7892849B2. This litigation confirms Roche is willing to assert both patents in federal court against competing strip products. The TRUE METRIX® product line was specifically named, but the claims may read broadly enough to implicate other strip architectures in the point-of-care glucose monitoring space.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US7727467B2 and US7892849B2 against your product specifications, identify relevant prior art that may limit claim coverage, and surface related Roche patents in the same family or technology cluster. For R&D and product teams developing next-generation glucose biosensor strips, an early-stage FTO analysis against this portfolio is a commercially prudent step before scale-up or market entry.
Run a freedom-to-operate analysis on US7727467B2 to assess your product’s exposure
Run FTO in Eureka →Similar Blood Glucose Diagnostic Patent Cases in Delaware District Court
Explore related patent infringement actions involving blood glucose test strip and biosensor technology litigated in Delaware District Court.
What this case signals for the blood glucose diagnostics IP landscape
A with-prejudice dismissal after 500 days suggests substantive negotiation — not a simple walkaway. Here is what IP teams need to know.
The patents survive: Roche retains enforcement rights against all others
Dismissal with prejudice binds only the two named parties. US7727467B2 and US7892849B2 remain valid, enforceable patents. Any manufacturer of blood glucose test strips with technology overlapping these claims faces the same litigation exposure that drove Trividia to resolve after 500 days. Monitoring Roche’s enforcement posture should be a standing agenda item for competitors.
Mutual cost-bearing is a red flag for a commercial deal, not litigation defeat
When parties each bear their own costs in a with-prejudice stipulation, it strongly suggests a negotiated resolution — a license, cross-license, or supply arrangement — rather than one party simply capitulating. IP teams and business development functions at diagnostics companies should treat this as a signal that Roche is willing to license these assets under the right commercial terms.
Roche v Trividia — key questions answered
Roche Diabetes Care asserted two patents: US7727467B2 (application US10/871673) and US7892849B2 (application US12/389954), both covering blood glucose test strip technology. The accused products were Trividia’s TRUE METRIX® PRO Test Strips and TRUE METRIX® Test Strips.
The case was dismissed pursuant to a joint stipulation under Federal Rule of Civil Procedure 41(a)(1)(A)(ii). The parties agreed to dismiss all claims and counterclaims with prejudice, with each side bearing its own costs. The public record does not disclose the commercial terms, if any, that accompanied the stipulation — but mutual cost-bearing typically suggests a negotiated resolution.
No. A dismissal with prejudice in a stipulated settlement binds only the named parties. US7727467B2 and US7892849B2 remain valid and enforceable patents. Roche retains full rights to assert them against other parties. The dismissal solely precludes Roche from re-filing the same claims against Trividia Health.
The case lasted approximately 500 days, from filing on June 4, 2024 to closure on October 17, 2025. This duration is consistent with a pre-trial resolution, likely following early discovery or claim construction proceedings in Delaware District Court.
Each party agreed to bear its own attorneys’ fees and costs, with no fee-shifting award. Under U.S. patent law, fee-shifting is available under 35 U.S.C. § 285 in exceptional cases. The absence of any fee award here suggests neither party sought or obtained an exceptional case finding, which is consistent with a negotiated commercial resolution rather than a clear litigation victory for either side.
PatSnap Eureka searches patents and litigation data to answer instantly.